RALEIGH,
N.C., July 31, 2024 /PRNewswire/ -- Eximia
Research announces the integration of Tidewater Clinical Research
into its national network of clinical trial sites. This strategic
development unites Tidewater's
longstanding expertise in Women's Health and Ophthalmology with
Eximia's extensive clinical trial experience and resources. Since
its inception in 1994, Tidewater
has led advancements in Women's Health through clinical trials in
the Hampton Roads/Eastern Virginia region, boasting a
substantial patient database and a strong network of investigators.
The addition of Tidewater's 97,000
patients brings Eximia's total patient volume up to nearly one
million patients nationwide.
With this acquisition, under the leadership of Dr. Ella Grach, CEO, Eximia is set to broaden their
impact on patient health in the mid-Atlantic US, building upon the
existing presence nationwide. Together, the sites will advance
medical research in specialized therapeutic areas, reinforcing
their commitment to the community and the broader medical and
pharmaceutical industry.
"We are excited to welcome Tidewater Clinical Research to the
Eximia network," says Grach. "Their expertise in Women's Health and
Ophthalmology complements our mission to drive innovation and
improve patient outcomes. This acquisition enhances our ability to
serve diverse populations and support groundbreaking clinical
research nationwide."
"Tidewater Clinical Research is proud to announce our
integration into the Eximia Research Network, marking a significant
step forward in enhancing clinical research accessibility and
quality of care for diverse patient populations," says Kelly Fleming, co-founder of Tidewater. April
Rusch, co-founder, adds, "Under the Eximia umbrella,
Tidewater is poised to broaden its
impact on patient health and contribute to the advancement of
medical research in ever-expanding medical subspecialty areas,
reinforcing its commitment to the community and the pharmaceutical
industry at large."
Tidewater Clinical Research joins Eximia's growing national
network of integrated sites, and their respective practice leaders
who welcome the new team as the network expands into Virginia. Doug
Surowitz, President of Health Awareness, LLC, a prominent
research company with two Florida
locations acquired by Eximia in 2023, states "Over the course of 10
years I've known Dr. Grach, I've cultivated a deep respect for her
capabilities in building site networks and understanding site
operations. The team she has built with Eximia and their strategic
growth plans continue to impress me. With continued growth,
including the recent addition of Tidewater Clinical Research, we
look forward to expanding our therapeutic capabilities and
incorporating enhanced systems and technology in this evolving
industry."
International Clinical Research (ICR), another recent addition
to Eximia in Tennessee and
Florida, includes a free-standing
Phase I trial site in Sanford, FL.
President of ICR, Brian Casteel,
adds, "The opportunity for consolidation in the fragmented clinical
research site industry will significantly enhance the value
proposition we offer our clients. We were impressed by the
organization's commitment to healthcare and their strategic
integration approach. Leadership's extensive experience and
methodical assembly of a team of industry professionals were key
factors in our decision to join Eximia. Leveraging Eximia's
resources will help us better serve our biotech and pharmaceutical
clients and expand our services beyond dermatology," he
concludes.
Eximia Research continues to grow its presence and patient panel
across the country, with sites from coast to coast in ethnically
diverse areas. This national reach ensures a wide range of patient
demographics, enhancing the quality and applicability of clinical
trial results. Recent acquisitions include prominent sites
specializing in various therapeutic areas, further solidifying
Eximia's position as a national leader in clinical research.
About Eximia Research Network:
Eximia is a multi-site, multi-therapeutic, clinical research
site network serving pharmaceutical, biotech companies and CROs and
providing Phase I-IV research services across a diverse range of
therapeutic indications, including neurology, psychiatry,
dermatology, vaccines, gastroenterology and metabolic disorders)
with access to underrepresented patient populations.
At Eximia, patients come first. By championing their needs with
patient-centric care, we make a difference in their lives and the
communities we serve.
Eximia is your trusted partner in clinical research, where we
merge decades of experience, unwavering commitment to excellence,
and flawless execution to drive the future of research and
healthcare innovation. For more information, please
visit: www.eximiaresearch.com.
About Tidewater Clinical Research Since 1994, Tidewater
Clinical Research has been at the forefront of Women's Health
research in the Hampton
Roads/Eastern Virginia
region. With a substantial patient database and a strong network of
investigators, Tidewater has
conducted numerous clinical trials that have significantly advanced
medical knowledge and patient care.
About VSS VSS is a private equity firm that partners with
entrepreneurs and management teams to help grow their businesses.
With a focus on healthcare, business services, and education, VSS
provides flexible capital solutions and strategic support to drive
long-term value creation.
CONTACT: Andrea Clement,
abc@clem.co
View original content to download
multimedia:https://www.prnewswire.com/news-releases/eximia-research-network-expands-into-virginia-with-integration-of-tidewater-clinical-research-302210547.html
SOURCE Eximia Research